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Purpose: The management of thyroid nodules of indeterminate cytology is controver-
sial. Our study aimed to establish the frequency and significance of H-,K-,N-RAS, TERT 
promoter, and BRAF gene mutations in thyroid nodes of indeterminate cytology and to 
assess their potential usefulness in clinical practice.
Methods: H-,K-,N-RAS, TERT promoter and BRAF gene mutations were examined in a 
series of 199 consecutive nodes of indeterminate cytology referred for surgical excision.
results: 69/199 (35%) were malignant on histopathological review. RAS mutations 
were detected in 36/199 (18%), and 19/36 cases (53%) were malignant on histological 
diagnosis. TERT promoter mutations were detected in 7/199 (4%) nodules, which were 
all malignant lesions. BRAF mutations were detected in 15/199 (8%), and a BRAF K601E 
mutation was identified in 2 follicular adenomas and 1 noninvasive follicular thyroid neo-
plasm with papillary-like nuclear features. Altogether, this panel was able to identify 48% 
of the malignant lesions, achieving a specificity, positive predictive value, and negative 
predictive value for malignancy of 85, 62, and 75%, respectively.
conclusion: The residual malignancy risk in mutation-negative nodes is 25%. These 
nodes still need to be resected, but mutation analysis could help to orient the appropri-
ate surgical strategy.
Keywords: thyroid nodules, indeterminate thyroid cytology, TERT promoter mutations, H-,K-,N-RAS mutations, 
BRAF mutations
inTrODUcTiOn
Fine-needle aspiration (FNA) cytology is the gold standard for the nonsurgical assessment of thyroid 
nodules, but it is unable to exclude cancer in one in four cases, which are labeled as “indeterminate” 
(1). According to the Italian Society of Anatomic Pathology and Cytology (SIAPEC) Consensus 
Statement, this “indeterminate” category is very heterogeneous, including cytological patterns that 
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range from follicular types and Hürtle cell lesions to scant atypi-
cal features. The cancer risk varies, reportedly averaging around 
26% in the largest series (2, 3). A proposed updated classification 
divides atypical cellular lesions into two categories, as explained 
in the SIAPEC 2014 Consensus Statement (4). Indeterminate 
lesions are separated into TIR 3A and TIR 3B, with an estimated 
malignancy risk below 10% for the former, and around 15–30% 
for the latter. The studies published to date are not enough to 
confirm these malignancy risk predictions, so there is still uncer-
tainty regarding the clinical approach to such nodules. To orient 
patient management, reference might be made to the malignancy 
risk of the extensively studied Bethesda classification. Any 
comparisons drawn between the indeterminate categories of 
the Bethesda and SIAPEC classifications should be considered 
with caution, however, for several reasons. For instance, atypia 
and follicular lesions of undetermined significance (AUS/FLUS) 
also includes cytological/nuclear atypia in the Bethesda system, 
which would convert a TIR 3A into a TIR 3B in the SIAPEC 
system (5). Such an unclear picture sometimes makes it difficult 
to manage patients with thyroid nodules of indeterminate cytol-
ogy and to choose between surveillance and diagnostic surgery. 
In fact, most of such patients undergo diagnostic surgery, but 
only a minority of their surgically resected nodules prove to be 
malignant (6). Thyroid lobectomy can be performed for solitary 
nodules, but then patients need a second surgical procedure 
to complete the thyroidectomy if histology identifies them as 
malignant. A more accurate preoperative diagnosis of cancer 
in thyroid nodules would enable such unnecessary or two-step 
surgery to be avoided.
In this clinical setting, molecular profiling has been suggested 
as a way to diagnose nodules of indeterminate cytology more 
accurately (7), and rule cancer in or out in the light of the test’s 
positive predictive value (PPV) or negative predictive value 
(NPV), respectively.
Among the various molecular testing approaches, searching 
for BRAF and H-, K-, and N-RAS point mutations is currently the 
most widely used for thyroid nodules of indeterminate cytology. 
BRAF point mutations are the most common gene mutations in 
thyroid cancer, occurring in 45% of papillary thyroid carcinomas 
(PTC), 20–40% of poorly-differentiated thyroid carcinomas 
(PDTC), and 30–40% of anaplastic thyroid carcinomas (ATC) 
(8, 9), while they are rarely seen in follicular thyroid carcinomas 
(FTC). BRAF V600E mutation testing has a high specificity 
for malignancy, but its sensitivity is too low to rule out cancer 
reliably (10). Mutational analysis therefore needs to consider 
other mutations too, such as H-RAS, K-RAS, and N-RAS point 
mutations. RAS mutations occur in 10–20% of PTC (11), 36–48% 
of FTC, and 20–40% of PDTC and ATC (10), but they are not 
specific for thyroid malignancy and they also occur in follicular 
adenoma (FA).
Telomerase activation is considered a hallmark of cancer 
because it is frequently activated in many human cancers, but 
not expressed in most normal tissues. TERT promoter mutations 
have recently been described in thyroid cancers deriving from 
follicular cells (12), occurring in 11% of PTC, 17% of FTC, 43% of 
PDTC, and 40% of ATC (13). Thyroid tumors carrying TERT pro-
moter mutations generally have more aggressive characteristics 
and higher tumor recurrence and mortality rates (13). TERT 
promoter mutations therefore have potential as novel diagnostic 
and prognostic markers in the setting of thyroid cancer.
Our study aimed (1) to establish the frequency and sig-
nificance of RAS, TERT promoter, and BRAF gene mutations in 
a large series of patients undergoing thyroid surgery for a nodule 
of indeterminate cytology and (2) to examine the potential utility 
of these mutations in clinical practice.
MaTerials anD MeThODs
Fna samples and Fna Procedures
The study involved 199 FNA samples of indeterminate cytol-
ogy obtained from thyroid nodules in 199 consecutive patients 
referred for surgical excision from December 2012 to May 2016. 
At our institution, BRAF and H-, K-, and N-RAS mutation 
analysis in FNA samples is standard procedure for single thyroid 
nodules and/or those with suspect features on ultrasonography. 
Molecular analysis for somatic mutations of TERT promoter was 
performed retrospectively. All studies were performed in accord-
ance with the guidelines proposed in the Declaration of Helsinki. 
The present study was notified to our Local Ethical Committee 
(Azienda Ospedaliera di Padova, code number: 42109) and all 
patients (including the parent/guardian on behalf of the minors) 
gave their written informed consent to the use of their thyroid 
cytology findings for research purposes. In this sample of patients, 
165/199 (83%) underwent total thyroidectomy, 25/199 (13%) had 
a lobectomy, and 9/199 (4%) a two-step thyroidectomy.
Of the 199 cases collected, the first 88 were classified according 
to the SIAPEC 2007 classification, and the remainder (111 cases) 
according to the revised version published during the course of 
the study (SIAPEC 2014) (4).
BRAF and RAS Mutation analysis
DNA was isolated from FNA samples using the QIAamp DNA 
Micro kit (Qiagen, Italy) according to the manufacturer’s protocol. 
The BRAF (NM_004333.4) status of exon 15 was assessed by direct 
sequencing. The primers and PCR reaction protocol have been 
described elsewhere (14). Exons 2 and 3 of H-RAS (NM_005343.2), 
K-RAS (NM_033360.2), and N-RAS (NM_002524.3) were ana-
lyzed by direct sequencing, as described elsewhere (15, 16).
TERT Promoter analysis
The TERT proximal promoter (NM_198253.2) was amplified 
from FNA samples using the amplification conditions described 
elsewhere (17).
statistics
Sensitivity, specificity, PPV, and NPV were calculated for each 
mutation, and for combined methods, considering the histo-
logical diagnosis as the gold standard. Group comparisons of 
categorical variables were performed using the chi-square test. 
A p-value of <0.05 was considered significant in all tests. All 
statistical analyses were performed using MedCalc for Windows, 
version 17.6.
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.Table 1 | Final histological classification of 199 cytologically indeterminate 
nodules.
histological result numerosity
Benign: n = 130/199 (65%) FA 87
HN 29
WDT-UMP 6
NIFTP 8
Malignant: n = 69/199 (35%) CV-PTC 24
FV-PTC 14
FTC-MI 16
FTC-WI 13
PTC/FTC 1
MTC 1
FA, follicular adenoma; FTC-MI, minimally invasive follicular thyroid carcinoma; FTC-
WI, widely invasive follicular thyroid carcinoma; HN, hyperplastic nodule; CV-PTC, 
classical variant of papillary thyroid carcinoma; FV-PTC, follicular variant of papillary 
thyroid carcinoma; MTC, medullary thyroid cancer; NIFTP, noninvasive follicular 
thyroid neoplasm with papillary-like nuclear features; PTC/FTC, mixed papillary thyroid 
carcinoma and follicular thyroid carcinoma; WDT-UMP, well-differentiated tumor of 
uncertain malignant potential.
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resUlTs
Patient statistics
Of the 199 patients included in our study, 155 (78%) were 
female and 44 (22%) were male. The mean age of the patients 
was 50 years (median 49 years). Among the 199 indeterminate 
fine-needle aspirates, 69 (35%) were classified as malignant on 
histopathological review (final histologies are given in Table 1). 
In the group of 111 patients classified according to the SIAPEC 
2014 system, 63 were TIR 3A and 48 were TIR 3B. Fourteen out of 
63 cases (22%) in the TIR 3A group, and 28/48 (58%) in the TIR 
3B group proved malignant at histology. A significant correlation 
emerged between malignancy and a TIR 3B diagnosis (p: 0.004 by 
chi-square analysis).
RAS Mutation Testing
RAS mutations were the most common, detected in 36/199 (18%) 
patients, and occurring in 28% (19/69) of the malignant nodules. 
Six nodules revealed an H-RAS mutation at codon 61, and one at 
codon 13. Three nodules carried a K-RAS mutation at codon 61, 
and two at codon 12. There were also 24 nodules with an N-RAS 
mutation at codon 61 (Table 2). Among the 36 patients exhibiting 
a somatic RAS mutation, 19/36 (53%) were malignant at histology 
(Table 3). Table 3 shows the sensitivity, specificity, PPV, and NPV 
for malignancy of these RAS mutations.
BRAF Mutation Testing
BRAF mutations were detected in 15/199 indeterminate thyroid 
nodules (8%), and in 12/69 (17%) thyroid malignancies. The 
classic c.1799T>A (p.V600E) mutation was found in 10/15 inde-
terminate cases (67%). Two rare BRAF mutations were identified: 
(i) a point c.1801A>G mutation (p.K601E) in 4 patients; and 
(ii) an in-frame triplet deletion c.1799_1801delTGA (p.V600_
K601>E) with no frame-shift in 1 patient (Table 2). The sensi-
tivity, specificity, PPV, and NPV for malignancy of these BRAF 
mutations are given in Table 3.
Table 3 | Frequency, sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV), and histological correlations of H-,K-,N-RAS, 
TERT promoter, and BRAF mutations.
Malignant 
histology 
(n = 69/199, 35%)
benign histology 
(n = 130/199, 
65%)
RAS (n = 36/199, 
18%)
n = 19/36, 53%
6 CV-PTC
7 FV-PTC
1 PTC/FTC
4 FTC-WI
1 FTC-MI
n = 17/36, 47%
11 FA
4 WDT-UMP
2 NIFTP
Sensitivity: 28%
Specificity: 87%
PPV: 53%
NPV: 69%
TERT promoter 
(n = 7/199, 4%)
n = 7/7, 100%
3 FV-PTC
4 FTC-WI
n = 0/7, 0% Sensitivity: 10%
Specificity: 100%
PPV: 100%
NPV: 68%
BRAF (n = 15/199, 
8%)
n = 12/15, 80%
9 CV-PTC
2 FV-PTC
1 FTC-WI
n = 3/15, 20%
2 FA
1 NIFTP
Sensitivity: 17%
Specificity: 98%
PPV: 80%
NPV: 69%
BRAF K601E 
(n = 4/199, 2%)
n = 1/4, 25%
1 FTC-WI
n = 3/4, 75%
2 FA
1 NIFTP
Sensitivity: 1%
Specificity: 98%
PPV: 25%
NPV: 65%
BRAF mutations 
other than K601E 
(n = 11/199, 6%)
n = 11/11, 100%
9 CV-PTC
2 FV-PTC
n = 0/11, 0% Sensitivity: 16%
Specificity: 100%
PPV: 100%
NPV: 69%
Any mutation 
(n = 53/199, 27%)
n = 33/53, 62% n = 20/53, 38% Sensitivity: 48%
Specificity: 85%
PPV: 62%
NPV: 75%
FA, follicular adenoma; FTC-MI, minimally invasive follicular thyroid carcinoma; FTC-WI, 
widely invasive follicular carcinoma; PTC, papillary thyroid carcinoma; CV-PTC, classical 
variant of papillary thyroid carcinoma; FV-PTC, follicular variant of papillary thyroid 
carcinoma; NIFTP, noninvasive follicular thyroid neoplasm with papillary-like nuclear 
features; PTC/FTC, mixed papillary thyroid carcinoma and follicular thyroid carcinoma; 
WDT-UMP, well-differentiated tumor of uncertain malignant potential.
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TERT Promoter Mutation Testing
TERT promoter mutations were detected in 7/199 (4%) nodules. 
There was no overlap between C228T and C250T mutations, the 
former being more prevalent than the latter. Only 2/7 patients 
carried an isolated somatic TERT promoter mutation, one a 
C228T and the other a C250T (both FTC-WI). In 5/7 nodules, the 
TERT promoter mutation was associated with another mutation 
in the H-, K-, N-RAS, or BRAF oncogenes (Table 2). No TERT 
promoter mutations were found in non-cancerous lesions, so 
their specificity and PPV for malignancy was 100%, while their 
sensitivity and NPV were 10 and 68%, respectively (Table 3).
combined Molecular Panel
Fine-needle aspiration samples were positive for gene mutations 
in at least one analysis in 53/199 cases (27%) (Table 3), and 33/53 
(62%) of these mutated nodules were malignant. Thirty-three of 
the 69 malignant nodules carried a mutation, so the panel was 
able to identify 48% of the malignant lesions. The panel thus 
achieved a sensitivity, specificity, PPV, and NPV for malignancy 
of 48, 85, 62, and 75%, respectively, giving a posttest probability 
of cancer of 62% (PPV) in indeterminate nodules found positive 
for gene mutations. This corresponds to a 27% improvement in 
the posttest over the pretest prediction of the cancer risk. For 
indeterminate nodules proving negative for mutations, on the 
other hand, the predicted cancer risk decreased from 35% pretest 
to 25% posttest (Table 3). A distinction between TIR 3A and TIR 
3B was available for 111 nodules: in the presence of any gene 
mutation, the panel revealed a 50% sensitivity, 78% specificity, 
37% PPV, and 84% NPV for predicting the cancer risk in the TIR 
3A category, and percentages of 39, 85, 79, and 50%, respectively, 
in the TIR 3B category.
DiscUssiOn
Our objectives in this study were to examine the frequency and 
significance of H-, K-, and N-RAS, TERT promoter and BRAF 
gene mutations in a large monocentric series of cytologically 
indeterminate thyroid nodules and to explore the utility (if any) 
of such a combined gene mutation analysis in terms of improving 
indeterminate thyroid nodule characterization prior to surgery.
To date, this is the largest monocentric European series of 
RAS-mutated cytologically indeterminate thyroid nodules with 
a histological diagnosis. RAS mutations were identified in 18% 
of the indeterminate nodules in our series, and proved to be 
the most common mutations. This percentage is higher than 
hitherto reported in patients undergoing thyroid surgery, which 
has been about 12% in other European series (18, 19), and as low 
as 6% in American series (7). On the other hand, it was 11.5% 
when Nikiforov et  al. restricted their assessment to patients 
who underwent surgery with an AUS/FLUS, or with a follicular 
neoplasm or suspected follicular neoplasm (FN/SFN) cytology 
(7). Cancer was found in 53% of the RAS-mutated nodules in our 
series, a considerably lower proportion than the 85% reported in 
American series (7), but much higher than the 18% identified in 
another recent Italian report (20) involving only 11 RAS-mutated 
patients who underwent surgery, and whose cytologies were 
mostly benign. On the other hand, the cancer occurrence rate in 
our RAS-mutated nodules was comparable with that of another 
European series (18), in which the significance of the mutation 
was analyzed in a similar patient setting.
As for the frequency and significance of BRAF mutations in 
cytologically indeterminate thyroid nodules, the percentage of 
mutated nodules in our series was 8%, which is slightly higher 
than reported elsewhere in the literature for indeterminate 
nodules, i.e., 5% in a recent meta-analysis on nine studies, and 
6% in a large individual study published after the meta-analysis 
(18, 21). So, BRAF testing alone has a low sensitivity (17%) in 
this setting. In addition, the BRAF K601E mutation needs to 
be considered separately because of its low probability of being 
associated with cancer: 3/4 BRAF K601E-mutated nodules in our 
series were benign. Two of the 3 patients harboring this mutation 
with a benign histology revealed FA with a microfollicular growth 
pattern, while the third had a noninvasive follicular thyroid neo-
plasm with papillary-like nuclear features (NIFTP). These three 
patients’ slides were reviewed to confirm their histopathological 
diagnosis. They were not the first cases to be reported of FA 
associated with a BRAF K601E mutation (22, 23), but—to our 
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knowledge—ours is the first report of a BRAF K601E mutation 
occurring in a NIFTP.
This is also the largest monocentric study to have investigated 
the frequency and significance of TERT promoter mutations 
in indeterminate thyroid FNA samples. With the exception of 
ThyroSeq. v2 (validated in the setting of FN/SFN cytologies), 
commercially available molecular panels for thyroid nodules 
found indeterminate on FNA do not include TERT promoter 
analysis (24). We aimed to ascertain the value of testing TERT 
promoter mutation analysis in a large collection of indeterminate 
nodules (including cytologies with less aggressive features than 
those in the FN/SFN category) to see if it might be useful and 
cost-effective to include it in such commercial panels. In our 
series, TERT mutations were found in 7/199 (4%) FNA samples, 
and in 7/69 (10%) histologically confirmed malignant nodules. 
All but two cancers found positive for TERT promoter mutations 
(5/7) also harbored another RAS or BRAF gene mutation. TERT 
promoter mutation testing alone thus revealed a low diagnostic 
sensitivity in indeterminate FNA samples, but a 100% specificity. 
We only found TERT promoter mutations in follicular-derived 
thyroid cancer with a follicular growth pattern—4/7 cases were 
widely invasive FTC (FTC-WI), and 3/7 were follicular variant 
of PTC (FV-PTC)—while none of the classical PTC in our series 
revealed any TERT mutations. All the FTCs harboring TERT 
promoter mutations were widely invasive, consistently with the 
literature correlating these mutations with a more aggressive 
disease and a worse prognosis. It is worth noting that one patient 
harboring a TERT promoter C250T point mutation also carried a 
BRAF K601E mutation: the association between TERT promoter 
and BRAF V600E mutations has been amply described in the 
literature (13), but ours is the first report (to our knowledge) 
of an association between TERT promoter and BRAF K601E 
mutations. This case seems particularly interesting because 
it is only the fifth case of FTC associated with a BRAF K601E 
mutation to be reported in the literature (22, 25–27). Three of the 
five known FTCs with the BRAF K601 mutation had minimal 
capsular and vascular invasion, consistent with the tendency of 
this mutation to be associated with low-grade cancers (22, 26, 27). 
The fourth (25) also harbored a PIK3CA mutation and the patient 
had extensive angio-invasion. Our case is therefore the second 
in which FTC harboring a BRAF K601E mutation is associated 
with extensive vascular invasion. We surmise that the BRAF 
K601E and TERT C250T mutations worked in synergy in the 
pathogenesis of our patient’s FTC: this tumor’s tendency to have 
more aggressive phenotypic characteristics may be due not only 
to the presence of the TERT promoter mutation, but also to its 
association with the BRAF K601E mutation. Given the strong 
association between TERT promoter and RAS mutations, and the 
case of the former being combined with a BRAF K601E mutation, 
our TERT promoter mutation analysis was able to identify only 
two additional cases of cancer in our series, so it was of little use 
for cancer identification purposes, in this class of cytologies at 
least. On the other hand, RAS and K601E mutations alone carry 
a low-to-moderate cancer risk (53% for the former and 25% for 
the latter), so the identification of a TERT promoter mutation 
might still be useful to the clinician in the setting of indeterminate 
nodules.
Returning to the usefulness of combined molecular panels, 
their use raised the cancer risk for indeterminate thyroid nodules 
found positive for genetic mutations to 62% (up 27% with respect 
to the pretest level), which is similar to the risk associated with 
TIR 4 lesions. Our PPV of 62% is lower than in an American 
series (in which it ranged from 87 to 95%), but comparable with 
the percentage seen in other European series. This disparity 
may be due to the higher percentage of cancer documented in 
American RAS-mutated indeterminate nodules, possibly because 
the Bethesda and SIAPEC classifications do not perfectly overlap 
(7, 18), and/or because our panel did not include RET/PTC and 
PAX8/PPARG rearrangement analysis. The introduction of the 
new histopathologic nomenclature of NIFTP may have played a 
part too in reducing the PPV of molecular panels for indetermi-
nate lesions, as expected (28). Differences in detection methods 
could have played a role as well. Histological correlation demon-
strated that applying our panel to indeterminate thyroid nodules 
prompted the identification of 48% of the malignant lesions, an 
efficiency in identifying cancer that resembles the results achieved 
by Eszlinger et al. in their monocentric European study (18).
Our study has some limitations to consider. First, it was 
conducted on a consecutive series of patients referred for sur-
gery, which is probably why their pretest probability of cancer 
was rather higher than expected (35% vs 25–30%), giving rise 
to a clinical setting in which “rule-in” molecular tests might 
be particularly effective. This is certainly not the first series of 
cytologically indeterminate thyroid nodules with such a high 
percentage of cancers (29), however. At our institution, FNA 
cytology is only performed for isolated nodules and those with 
suspect features on ultrasound, and it is well known that the 
presence of even one suspicious sonographic feature raises the 
cancer risk in indeterminate nodules (30). In addition, not all 
the patients in our series were classified according to the latest 
SIAPEC classification, and this prevented us from thoroughly 
examining the utility of molecular analysis in nearly half of our 
sample, though there was evidence of a markedly higher NPV for 
cancer in TIR3A than in TIR 3B patients (84 vs 50%). In other 
words, the utility of the gene mutation panel may be greater when 
the cancer rate is better defined.
In conclusion, we feel that the outcome of molecular test-
ing, as done in our large series of cytologically indeterminate 
thyroid nodules, can orient physicians’ and surgeons’ patient 
management in clinical practice. In the light of our findings, 
92 patients could have been spared total thyroidectomy and 
treated adequately with a lobectomy, and 4 total thyroidectomies 
would have been performed in one instead of two steps, possibly 
with fewer side effects. On the other hand, five unnecessary 
total thyroidectomies would have been performed in patients 
revealing genetic mutations associated with a benign histology. 
It is worth adding that there is currently a move toward novel 
approaches for the management of thyroid nodules in an effort 
to limit their over-diagnosis and over-treatment. According 
to the new American Thyroid Association guidelines, thyroid 
lobectomy suffices for malignant nodules smaller than 4 cm, with 
no extrathyroidal extension or clinical evidence of lymph node 
metastases (Recommendation 35) (1). Prospective and controlled 
studies resulting from the application of these guidelines are still 
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lacking, however. Meanwhile, molecular testing may be useful for 
stratifying cytologically indeterminate categories for the purpose 
of deciding on their surgical treatment. The sensitivity of TERT 
promoter mutation for the purpose of predicting cancer risk is 
low in the indeterminate category, so testing for this mutation 
may not be cost-effective. In such a particular setting, however, 
where it remains mandatory to recognize rare cancers with an 
aggressive behavior, testing for TERT promoter mutations might 
still prove its worth, particularly in the preoperative setting.
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